Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sanofi, GSK seek to have an adjuvanted COVID-19 vaccine ready by late 2021

By Chris Newmarker | April 21, 2020

GSK SanofiSanofi and GSK recently announced that they have signed a letter of intent to collaborate on an adjuvanted vaccine for COVID-19 — with a goal of having the vaccine available by the second half of 2021.

Sanofi is contributing its S-protein COVID-19 antigen. The company’s recombinant DNA technology produced an exact genetic match to proteins found on the surface of the coronavirus. Sanofi researchers took the DNA sequence encoding the antigen and combined it with the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the U.S.

GSK meanwhile has its pandemic adjuvant technology. Using an adjuvant can be of particular importance in a pandemic situation, according to the companies, because the adjuvant may reduce the amount of vaccine protein required per dose. The result is the availability of more vaccine doses to protect more people from the virus.

“As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus,” Sanofi CEO Paul Hudson said in an April 14 news release.

GSK CEO Emma Walmsley thinks the partnership will help accelerate the global effort to develop a COVID-19 vaccine.

 


Filed Under: Drug Discovery, Drug Discovery and Development, Genomics/Proteomics, Infectious Disease
Tagged With: coronavirus, GSK, Sanofi
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50